Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

@inproceedings{Ginzler2012AtaciceptIC,
  title={Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial},
  author={Ellen M. Ginzler and Stephen Wax and Anand Rajeswaran and Samuel Copt and Jan L. Hillson and Eleanor L Ramos and Nora G. Singer},
  booktitle={Arthritis research & therapy},
  year={2012}
}
INTRODUCTION Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) and mycophenolate mofetil (MMF). METHODS This was a randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At… CONTINUE READING
80 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

, Vancouver , Canada . CS 12 . 6 and PO 2 . E . 23

  • D Wofsy, GB Appel, +5 authors L Lisk
  • Aspreva Lupus Management Study maintenance…
  • 2010

Aspreva Lupus Management Study maintenance results

  • D Wofsy, GB Appel, +5 authors L Lisk
  • 2010

The ALMS Study Group: Aspreva Lupus Management Study maintenance results

  • D Wofsy, GB Appel, +5 authors L Lisk
  • The 9th International Congress on SLE June
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…